The Significance of the RESORCE Trial in HCC

August 1, 2016
Bruno Daniele, MD

Bruno Daniele, MD, director, Department of Oncology and Medical Oncology, G. Rummo Hospital, Italy, discusses the significance of the RESORCE trial, which examined the use of regorafenib (Stivarga) as a treatment for patients with hepatocellular carcinoma (HCC).